Premium
Low response to high‐dose intravenous immunoglobulin in the treatment of acquired factor VIII inhibitor
Author(s) -
Crenier Laurent,
Ducobu Jean,
Des Grottes JeanMarin,
Cerny Jean,
Delaunoit Christian,
Capel Paul
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.d01-1965.x
Subject(s) - medicine , prednisone , antibody , expansive , intravenous immunoglobulins , gastroenterology , immunology , compressive strength , materials science , composite material
Prednisone is the classic first‐line therapy to suppress an acquired factor VIII inhibitor and may achieve complete remission in about 30% of patients. More recently, promising results have been reported with high‐dose intravenous immunoglobulin (IVIg). However, after an extensive review of the literature, we found only three complete remissions (12%) among the 26 assessable patients treated by IVIg. These data are in agreement with the low response to IVIg that we experienced in our series of patients. This study suggests that steroids should still be preferred to IVIg, an expansive therapy, to suppress an acquired factor VIII inhibitor.